Journal
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 63, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2022.103805
Keywords
Relapsing multiple sclerosis; Disease modifying therapy; Benefit-risk; Therapy switching; Relapse; Washout period
Categories
Ask authors/readers for more resources
Experts reached a consensus on treatment switching approaches in relapsing multiple sclerosis (RMS) through a modified Delphi process, providing up-to-date guidance on disease modifying therapy sequencing for optimal patient management.
Background: The increase in available disease modifying therapies (DMTs) for multiple sclerosis has led to greater emphasis on improving treatment sequencing paradigms. This article summarises the opinions from a panel of 25 experts on treatment switching approaches in relapsing multiple sclerosis (RMS).Methods: A modified Delphi consensus process was carried out to develop clinically relevant statements for aiding treatment decisions in patients with RMS between the 16th January and the 9th October 2019. A sub-group of two experts (core group) carried out an extensive review of the literature and formulated 106 statements for the expert panel to evaluate.Results: From a total number of 106 statements that were submitted to the expert panel for critical evaluation, consensus (at least 80% of the panelists agreed) was reached on 99 of them. These statements cover treatment objectives, reasons for DMT switching, suboptimal response criteria, strategies for treatment change and washout periods.Conclusion: The agreed statements provide up-to-date guidance on DMT sequencing for optimal patient management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available